All In Biotech

Drug Trial Radar · NCT05393193

POC HIV Testing and Early DTG Use for Infants

Point-of-Care HIV Testing and Early Dolutegravir Use for Infants

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Jul 4, 2022

Primary completion

Mar 16, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Harvard School of Public Health (HSPH)Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Botswana Harvard AIDS Institute Partnership; Ragon Institute of MGH, MIT and Harvard; Botswana Ministry of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to explore the feasibility of implementing targeted birth HIV testing of high-risk neonates using facility-based point-of-care (POC) HIV diagnostics, and to improve the ability to implement the best standard-of-care treatment possible. Infants found to be HIV infected will be immediately offered enrollment into a dolutegravir (DTG) antiretroviral treatment study cohort (if maternal consent is granted) or referred for treatment at a government facility. Infants who enter the study treatment cohort will be prospectively followed through 96 weeks of age. ART will follow Botswana guidelines.

Conditions

  • HIV

Interventions

  • Point-of-Care Cepheid Xpert HIV-1Diagnostic test

    Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.

  • DTG/ABC/3TCDrug

    Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of high-risk HIV-exposed infants identified and testedTime frame: within 72 hours of life
  2. Median time to HIV diagnosis and treatment-dose ARTTime frame: 7 days
  3. The proportion of children with HIV-1 RNA <40 copies/mL at 12 weeks on ARTTime frame: 12 weeks on ART
  4. The proportion of children with successful DTG-based treatment through 96 weeks on ARTTime frame: 96 weeks on ART
  5. The proportion of infants with grade 3 or 4 adverse events/hospitalization/deathTime frame: 96 weeks on ART

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Botswana Harvard Health Partnership

    Gaborone, Botswana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.